During the study period, 2100 children were hospitalized in the pediatric pulmonology department of the Albert Royer children’s hospital. Among them, 08 cases of spinal muscular atrophy were collected, representing an annual incidence of 0.76%. The average age of our patients was 9 ± 9 months with a range of 3 months to 32 months. The median was 6.5 months. The sex ratio was 7. Among the patients, 50% were from Dakar.

The notion of spinal muscular atrophy in the family was found in 25% of cases and family consanguinity in 62.5% of cases.

The vaccination status of patients was up to date in 6 cases according to the extended vaccination program of senegal (PEV).

A delay in psychomotor development was found in 100% of the children. Vaccination was up to date in 75% of children according to Senegal’s expanded vaccination program. In our study, severe malnutrition was found in 12.5% of cases.

Hypotonia and respiratory distress were found in 50% of cases.

Consciousness was preserved in 5 patients, a proportion of 62.5%. Normal voluntary motor skills were found in 6 patients (75%), a bilateral motor deficit of both limbs and flaccid paraplegia associated with paresis of the limbs were noted in 12.5% of cases. Superficial and deep sensitivity was preserved in 3 patients (37.5%).

Examination of the respiratory system revealed paradoxical breathing in 75% of cases. Respiratory distress, condensation syndrome and congestion were noted in 62.5% of patients. Figure 1 shows the distribution according to respiratory signs.

In 75% of cases the age of onset of symptoms was before 6 months (75% of cases).

However, in 12.5% of cases, it can be less or more than 18 months as shown in Table 1.

Electromyogram (EMG) was performed in 3 patients (37.5%) including

- The 2 cases concluded that there was a severe peripheral neurogenic process in all four limbs with damage to the axial muscles (sternocleidomastoid) where a large, poor, accelerated tracing with giant potentials was found in favor of infantile progressive spinal muscular atrophy type I (WERDNIG HOFFMAN).

- The other showed an axono-myelin sensory-motor polyneuropathy of the four limbs.

In our study, no cases benefited from genetic and molecular biology studies.

The average age of diagnosis was 8.5 months ± 8 with extremes ranging from 3 months to 30 months. According to the classification of the international ASI consortium we retained 6 cases of infantile spinal muscular atrophy type I and 2 cases of infantile spinal muscular atrophy type III.

Medical treatment was administered in 100% of patients. Four patients had benefited from respiratory physiotherapy, i.e. 50% of cases. Genetic counseling was carried out in one patient (12.5%). Gene therapy was not prescribed in our patients.

The outcome was immediately favorable in 2 patients or 25% of cases. Unfavorable outcome in 75% of cases with a death rate of 50%. The average age of death was 5.5 months ± 1 with extremes ranging from 3 to 7 months.

Long term was difficult to assess due to the loss of vision in several of the patients.

In our study, the average age of our patients was 9±9 with extremes of 3 months to 32 months. The median was 6.5 months, which is close to the study done in Morocco [6] and that in Chile [7] . On the other hand, the study carried out in Portugal [8] reported that the age of diagnosis was between 0 and 2 years. The age at diagnosis of spinal muscular atrophy varies and depends on the type and severity of the disease.

Furthermore, in our study, due to the fact that practitioners do not think early about the diagnosis, especially neonatal screening, and that parents are concerned late by the signs linked to this disease, the diagnosis is often made late. Consanguinity, as in all recessive diseases, is an important contributing factor in the emergence of spinal muscular atrophy. The consanguinity rate is significantly higher among couples who have given birth to children with ASI compared to couples without sick children. The figures range from 2.5 to 7.7% for marriages between relatives to 0.2% for a standard population [9] . In the Pearn series [10] , the difference was even more significant (5% to 0.1%). In our work, consanguinity was found in 5 cases or 62.5%, which matches the figures reported by the study carried out in Egypt [11] and that of the Constantine University Hospital [12] which were respectively 46% and 47 %.

Spinal muscular atrophy is a genetic disease with serious consequences. It is important to look for the presence or absence of similar cases in the family.

The survey by the French Association against Myopathies carried out in France [13] cited that 22% of patients had one or more people in their family affected by spinal muscular atrophy. This could be explained by the fact that in the case of a history of direct family ASI, the risk of developing ASI is increased. Therefore, early detection of at-risk cases is necessary in order to be able to implement appropriate measures to prevent the risk of having an ISA.

The most frequent reasons for consultation were hypotonia in 4 type I cases (50%) and respiratory distress present in 4 type I and III cases. According to SHAWKY [11] , the most common complaints were recurrent respiratory infections, hypotonia and muscle weakness in all type I patients (67.5%), followed by inability to walk in all type I patients. type II (27.3%), and functional impotence and difficulty walking in all type III patients (5.2%). Hypotonia is often the first clinical sign found in type I spinal muscular atrophy. Muscular paralysis progresses to affect the respiratory muscles such as the diaphragm, causing the paradoxical breathing found in certain cases of ISA. Respiratory muscle damage remains a poor prognosis criterion.

The genetic test makes it possible to obtain a definitive diagnosis in a very short time. It is often done straight away. However, in the literature it is reported that, in some cases, the doctor initially prescribes additional tests to guide the diagnosis: muscle enzyme measurements, electromyogram. Muscle biopsy is no longer necessary these days unless the result of the genetic test is ambiguous. [14] . In proximal spinal muscular atrophy linked to SMN1, the measurement of muscle enzymes shows CPK (creatine phosphokinase) generally low, indicating a process of loss of muscle fibers that is not very active. This examination thus makes it possible to rule out other neuromuscular diseases (muscular dystrophies, congenital myopathies, inflammatory myopathies, etc.), particularly in cases of type III spinal muscular atrophy and atypical forms of the disease [14] .

In people suffering from proximal spinal muscular atrophy linked to SMN1, the electromyogram, if carried out, shows that it is the nerve, in this case the motor neuron, which is primarily affected, explaining the muscular weakness found [14] . In our study, only EMG was performed in 3 patients (37.5%).

This is explained by the fact that its examinations are more available and accessible in industrialized countries than in our context and by the fact that the socio-economic level is low in our countries where patients have difficulty taking care of themselves.

The age at diagnosis in our series was before 6 months in 75% of cases.

In the Ge series [15] , the age of onset of the disease was between birth and the age of 9 months with an average of 3.1 months for type 1, and it varied between 2 to 18 months. With an average of 8.7 months for type 2 and he was between the age of 2 months to 5 years with an average of 21 months for type 3. Neonatal screening could help in early diagnosis and management adequate treatment of cases before symptoms set in. In our contexts the predominance of type I of the disease explains the fact that the age at diagnosis is before the acquisition of the sitting position.

Symptomatic medical treatment was administered to all patients. The symptomatic treatment consisted to respiratory physiotherapy and oxygene therapy.

Genetic counseling was carried out in one patient (12.5%). The management of infantile spinal muscular atrophy is multidisciplinary and must be started as early as possible. There is no treatment that can permanently cure patients. However, medical treatment is symptomatic [16] [17] . However, innovative therapies have been available for several years in developed countries and are considered as basic treatment in ISA [14] . Gene therapy can increase the life expectancy of patients, especially if it is started early. However, it does not completely cure the disease. This difference in care can be explained by the financial difficulties encountered by our patients in our countries, unavailability and inaccessibility of these innovative therapies.

The progression of proximal spinal muscular atrophy is specific to each person.

However, early and appropriate medical care can improve the quality of life of these patients [14] . However, infantile spinal muscular atrophy is a chronic disease, and in the absence of adequate care, there is a tendency at worsening, the evolution is not predictable. Serious complications can occur, even life-threatening. In this context our study showed an unfavorable evolution in 75% of cases with a death rate of 50%. The average age of death was 5.5 months ± 1 with extremes ranging from 3 to 7 months. In the long term, the evolution was difficult to assess due to the loss of sight of several of the patients.